Floatz logo

Bcma Car T Cells

Vasculitis

Zhejiang UniversityCell therapyEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Vasculitis cohort.

Asset / SponsorPhaseRating
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE
Northwestern University
Phase 2B
Infliximab
University of California, San Francisco
Phase 1/2CCC

Same molecule, other indications

Bcma Car T Cells is also rated in:

POEMS syndromeDormant
C
Indicative ·
39 / 100
View asset →
amyloidosisDormant
C
Indicative ·
39 / 100
View asset →
autoimmune hemolytic anemiaDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →